Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy.

Simple Summary: Here, we evaluated whether circulating tumor DNA (ctDNA) measured after neoadjuvant therapy (NAT) or surgery can help to assess tumor response and predict recurrence risk in patients with locally advanced rectal cancer, including those managed non-operatively (NOM). In this large rea...

Descripción completa

Detalles Bibliográficos

Publicado en:	Cancers Vol. 18; no. 4; pp. 589 - 606
Autores principales:	Chakrabarti, Sakti, Cohen, Stacey A., Tin, Antony, Dangl, Autumn, Chung, Ki Y., Tejani, Mohamedtaki A., Fakih, Marwan G., Chandana, Sreenivasa R., Donahue, Colleen A., George, Virgilio, Malla, Midhun, Aushev, Vasily N., George, Giby V., Ortiz, J. Bryce, Herter, Whitney K., Nagarajan, Arun, Weinberg, Benjamin A., Sharma, Vivek R., Botta, Gregory P., Cho, May
Formato:	research tables/charts Journal Article
Publicado:	MDPI Feb2026
Acceso en línea:	Ver este registro en EBSCOhost